Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease (VNS)
Primary Purpose
Crohn's Disease
Status
Terminated
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
vagus nerve stimulation (VNS)
Sponsored by
About this trial
This is an interventional treatment trial for Crohn's Disease focused on measuring Crohn's Disease, VNS, vagus nerve stimulation, inflammation, Inflammatory bowel diseases, TNF
Eligibility Criteria
Inclusion Criteria:
- Patients with CD involving the ileo-colon, diagnosed for at least 3 months prior to screening in flare (220<CDAI<450) of their disease despite a treatment reference (corticosteroids and/or immunosuppressives) with a stable dose will be included
- CRP>5mg/l and/or fecal calprotectin <100µg/l
- CDEIS > 7 (Crohn's disease endoscopic index of severity)
- Consenting patient
Exclusion Criteria:
- Known cardiac pathology
- VNS contraindication
- Anoperineal CD only or associated with ileocolic lesion
- Diagnosis of indeterminate colitis, positive stool culture for enteric pathogens
- CD Surgery within 3 months before screening
- Short small intestine (<1m)
- Koenig syndrome
- Intra-abdominal abscess
- Fistula with clinical or radiological abscess evidence
- Anoperineal CD with or without rectal involvement
- Ileostomy, colostomy, enteral or parenteral feeding
- Clinical condition medically or surgically unstable that, at the discretion of the investigator would not be compatible with the patient's participation in the study
- Any recent neoplasia, in the year prior to screening
Sites / Locations
- Grenoble university hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
VSN
Arm Description
VNS therapy
Outcomes
Primary Outcome Measures
Clinical remission 12 months after initiation of VNS
Clinical remission at 12 months :
Patient without corticoids or a dose of 20mg without dose adjustment (stable treatment) and without anti-TNF,
CDAI <150 or CDAI has dropped by at least 70 or 100 points (Δ70, Δ100) compared with the baseline CDAI
Stable immunosuppressive therapy.
Secondary Outcome Measures
Clinical remission 6 months after initiation of VNS
Clinical remission at 6 months :
Patient without corticoids or a dose of 20mg without dose adjustment (stable treatment) and without anti-TNF,
CDAI <150 or CDAI has dropped by at least 70 or 100 points (Δ70, Δ100) compared with the baseline CDAI
Stable immunosuppressive therapy
VNS tolerance
Description and frequency of adverse events
Assessment of VNS effectiveness with biological markers
Assessment of VNS effectiveness with biological markers of the pro-and anti-inflammatory status
Endoscopic and ultrasound Assessment of VNS effectiveness
Endoscopy : CDEIS (Crohn's Disease Endoscopic Index of Severity) Ultrasound : score Migaleddu V. and al, 2009
Assessment of the central effects of VNS
Evolution of :
Sleep cycle : duration of sleep stages, sleep latency, latency between the different sleep stages.
High-resolution Electroencephalogram (EEG): Spatiotemporal evolution of the spectral density of EEG power in the different frequency bands
Correlation between high-resolution EEG markers of autonomic nervous system
Evaluation of peripheral effects of VNS on sympatho-vagal balance
Evolution of cardiac variability markers using time and frequency analysis of electrocardiogram :
Frequency Analysis : LH, HF, LF/HF
Time analysis : RMS-SD, pNN50, NN50, average cardiac rhythm
Full Information
NCT ID
NCT01569503
First Posted
March 30, 2012
Last Updated
May 2, 2018
Sponsor
University Hospital, Grenoble
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Université Joseph Fourier, CRSSA : Centre Recherche Service Santé Armée
1. Study Identification
Unique Protocol Identification Number
NCT01569503
Brief Title
Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease
Acronym
VNS
Official Title
The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Terminated
Study Start Date
March 2012 (Actual)
Primary Completion Date
March 30, 2017 (Actual)
Study Completion Date
May 30, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Université Joseph Fourier, CRSSA : Centre Recherche Service Santé Armée
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether (VNS) Vagus Nerve Stimulation , is effective in the treatment of Crohn's disease.
Detailed Description
Inflammatory bowel diseases or IBD (Crohn's disease and ulcerative colitis) are chronic inflammatory diseases involving the digestive tract, in particular the small bowel and/or the recto-colon. IBD represent a public health problem in Gastroenterology. The etiopathogeny of IBD is multifactorial involving immunological, genetic, infectious and environmental factors. An overarching hypothesis is that an unbalance of the autonomic nervous system, represented by the sympathetic and parasympathetic nervous system (e.g. the vagus nerve) is part of the mechanisms underlying the pathophysiology of IBD. A dysautonomia has been observed in IBD patients and we have recently demonstrated that this dysautonomia was linked to psychological coping, in particular in Crohn's disease. Classically, the vagus nerve, a mixed nerve, has an anti-inflammatory role through its central afferents which secondarily stimulate the hypothalamic-pituitary adrenal axis. Recent data have shown that the anti-inflammatory properties of the vagus nerve also involve peripheral efferents via an interaction of acetylcholine with nicotinic receptors leading to an inhibition of TNF release by macrophages. Vagus nerve stimulation (VNS) is currently used for the treatment of some forms of epilepsy in Human via a stimulation of vagal afferents. We have recently validated a model of chronic VNS (3h/d for 5 days) in freely moving rats by stimulating vagal efferents and we have studied the anti-inflammatory properties of VNS in an experimental model of colitis in rats. VNS significantly decreased body weight loss due to colitis and had an anti-inflammatory effect by decreasing a multivariate index of inflammation. To date, medical treatment of IBD (e.g. 5-aminosalicylates, corticosteroids, immunosuppressives or biotherapies i.e. anti-TNF) is only suspensive. The aim of our project is to propose another type of anti-inflammatory treatment based on neurostimulation of vagal efferents. For this purpose, we aim to perform a pilot study in 10 patients with moderate to severe Crohn's disease despite a reference treatment (corticosteroids and/or immunosuppressives) using the anti-inflammatory properties of VNS as an alternative to anti-TNF therapy. Central and peripheral effect of VNS will be also evaluated by electroencephalographic and sympatho-vagal (heart rate variability) recordings. The finality, at term, is to use VNS as an alternative to the conventional anti-TNF therapy not devoid of side effects, in particular infectious, with the advantage to use an intrinsic anti-inflammatory (anti-TNF) system and to take cover of problems of adherence to treatment which are frequently observed in the medical treatment of IBD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn's Disease
Keywords
Crohn's Disease, VNS, vagus nerve stimulation, inflammation, Inflammatory bowel diseases, TNF
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)
8. Arms, Groups, and Interventions
Arm Title
VSN
Arm Type
Experimental
Arm Description
VNS therapy
Intervention Type
Device
Intervention Name(s)
vagus nerve stimulation (VNS)
Intervention Description
VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
Primary Outcome Measure Information:
Title
Clinical remission 12 months after initiation of VNS
Description
Clinical remission at 12 months :
Patient without corticoids or a dose of 20mg without dose adjustment (stable treatment) and without anti-TNF,
CDAI <150 or CDAI has dropped by at least 70 or 100 points (Δ70, Δ100) compared with the baseline CDAI
Stable immunosuppressive therapy.
Time Frame
12 months after initiation of VNS
Secondary Outcome Measure Information:
Title
Clinical remission 6 months after initiation of VNS
Description
Clinical remission at 6 months :
Patient without corticoids or a dose of 20mg without dose adjustment (stable treatment) and without anti-TNF,
CDAI <150 or CDAI has dropped by at least 70 or 100 points (Δ70, Δ100) compared with the baseline CDAI
Stable immunosuppressive therapy
Time Frame
6 months after initiation of VNS
Title
VNS tolerance
Description
Description and frequency of adverse events
Time Frame
12 months
Title
Assessment of VNS effectiveness with biological markers
Description
Assessment of VNS effectiveness with biological markers of the pro-and anti-inflammatory status
Time Frame
12 months
Title
Endoscopic and ultrasound Assessment of VNS effectiveness
Description
Endoscopy : CDEIS (Crohn's Disease Endoscopic Index of Severity) Ultrasound : score Migaleddu V. and al, 2009
Time Frame
12 months
Title
Assessment of the central effects of VNS
Description
Evolution of :
Sleep cycle : duration of sleep stages, sleep latency, latency between the different sleep stages.
High-resolution Electroencephalogram (EEG): Spatiotemporal evolution of the spectral density of EEG power in the different frequency bands
Correlation between high-resolution EEG markers of autonomic nervous system
Time Frame
At 6 weeks, at 6 months, at 12 months
Title
Evaluation of peripheral effects of VNS on sympatho-vagal balance
Description
Evolution of cardiac variability markers using time and frequency analysis of electrocardiogram :
Frequency Analysis : LH, HF, LF/HF
Time analysis : RMS-SD, pNN50, NN50, average cardiac rhythm
Time Frame
6 weeks, 6 months, 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with CD involving the ileo-colon, diagnosed for at least 3 months prior to screening in flare (220<CDAI<450) of their disease despite a treatment reference (corticosteroids and/or immunosuppressives) with a stable dose will be included
CRP>5mg/l and/or fecal calprotectin <100µg/l
CDEIS > 7 (Crohn's disease endoscopic index of severity)
Consenting patient
Exclusion Criteria:
Known cardiac pathology
VNS contraindication
Anoperineal CD only or associated with ileocolic lesion
Diagnosis of indeterminate colitis, positive stool culture for enteric pathogens
CD Surgery within 3 months before screening
Short small intestine (<1m)
Koenig syndrome
Intra-abdominal abscess
Fistula with clinical or radiological abscess evidence
Anoperineal CD with or without rectal involvement
Ileostomy, colostomy, enteral or parenteral feeding
Clinical condition medically or surgically unstable that, at the discretion of the investigator would not be compatible with the patient's participation in the study
Any recent neoplasia, in the year prior to screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruno BONAZ, MD, PHD
Organizational Affiliation
Grenoble university hsopital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grenoble university hospital
City
Grenoble
State/Province
Isere
ZIP/Postal Code
38043
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
21071287
Citation
Meregnani J, Clarencon D, Vivier M, Peinnequin A, Mouret C, Sinniger V, Picq C, Job A, Canini F, Jacquier-Sarlin M, Bonaz B. Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton Neurosci. 2011 Feb 24;160(1-2):82-9. doi: 10.1016/j.autneu.2010.10.007. Epub 2010 Nov 11.
Results Reference
background
PubMed Identifier
10839541
Citation
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000 May 25;405(6785):458-62. doi: 10.1038/35013070.
Results Reference
background
Learn more about this trial
Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease
We'll reach out to this number within 24 hrs